Galectin Therapeutics Inc. (GALT)

Market Cap	374.15M +14.5%
Revenue (ttm)	n/a
Net Income	-28.03M
EPS	-0.43
Shares Out	100.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,182
Open	3.680
Previous Close	3.640
Day's Range	3.660 - 3.840
52-Week Range	2.025 - 7.130
Beta	0.38
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 9
• Stock Exchange: Nasdaq
• Ticker Symbol: GALT
• Website: https://galectintherapeutics.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error